Chameleon Biosciences is a startup based in the United States, 1 tracked investor.
Based in the United States, Chameleon Biosciences is a startup. Brouky records 1 investor associated with the company.
Chameleon Biosciences develops next-generation adeno-associated virus (AAV) vectors with reduced immune response to enable repeat dosing and enhanced efficacy for gene replacement and editing therapies targeting diseases such as hemophilia and Niemann-Pick Type C.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.